

## DIVI'S LABORATORIES LIMITED

### UNAUDITED FINANCIAL RESULTS (STANDALONE) FOR THE QUARTER ENDED 30<sup>TH</sup> JUNE, 2013

(₹ in Lakhs)

Sl No.	Particulars	STANDALONE			
		Unaudited			Audited
		Quarter ended 30.06.2013	Quarter ended 31.03.2013	Quarter ended 30.06.2012	Year Ended 31.03.2013
	(1)	(2)	(3)	(4)	(5)
1	<b>Income from operations</b>				
	(a) Net Sales/Income from operations (Net of Excise Duty)	<b>51588</b>	64961	46841	212395
	(b) Other Operating Income	<b>127</b>	167	110	494
	<b>Total Income from operations (net)</b>	<b>51715</b>	65128	46951	212889
2	<u>Expenditure:</u>				
	a. Cost of materials consumed	<b>28389</b>	23317	17257	89790
	b. Purchases of stock-in-trade	<b>0</b>	0	0	9
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	<b>(10640)</b>	2091	(1174)	(10033)
	d. Employee benefits expense	<b>5303</b>	5386	4845	19120
	e. Depreciation and amortization expense	<b>2088</b>	2027	1748	7690
	f. Other Expenses	<b>8945</b>	9096	6869	31828
	Total Expenses	<b>34085</b>	41917	29545	138404
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	<b>17630</b>	23211	17406	74485
4	Other Income	<b>5342</b>	759	4066	4851
5	Profit from ordinary activities before finance costs & exceptional Items (3+4)	<b>22972</b>	23970	21472	79336
6	Finance Costs	<b>41</b>	62	41	178
7	Profit from ordinary activities after finance costs but before exceptional Items (5-6)	<b>22931</b>	23908	21431	79158
8	Exceptional items	0	0	0	0
9	<u>Profit from ordinary activities before Tax (7-8)</u>	<b>22931</b>	23908	21431	79158
10	Tax Expense:	<b>5460</b>	5725	4693	18016
11	<u>Net Profit from ordinary activities after Tax: (9-10)</u>	<b>17471</b>	18183	16738	61142
12	Extra-ordinary items (net of tax expense)	<b>0</b>	0	0	0
13	Net Profit (+)/Loss(-) for the period (11-12)	<b>17471</b>	18183	16738	61142
14	Share of profit / (loss) of associates	0	0	0	0
15	Minority Interest	0	0	0	0

16	Net Profit (+)/Loss(-) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	<b>17471</b>	18183	16738	61142
17	Paid-up Equity Share Capital (Face Value : Rs.2 per share)	<b>2655</b>	2655	2655	2655
18	Reserves excluding revaluation reserves as per balance sheet of previous accounting year				252673
19.i	Earnings per Share (before extraordinary items) (of Rs.2/- each) (not annualized):				
	a) Basic	<b>13.16</b>	13.70	12.61	46.06
	b) Diluted	13.16	13.70	12.61	46.06
19.ii	Earnings per Share (after extraordinary items) (of Rs.2/- each) (not annualized):				
	a) Basic	<b>13.16</b>	13.70	12.61	46.06
	b) Diluted	<b>13.16</b>	13.70	12.61	46.06

<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>				
1	Public shareholding - No. of shares - Percentage of shareholding	<b>63512190</b> <b>47.85%</b>	63512190 47.85%	63512190 47.85%	63512190 47.85%
2	Promoters and promoter group shareholding: a) pledged / encumbered b) non-encumbered: No. of shares Percentage of shares (as a % of the total shareholding of the promoter group) Percentage of shares (as a % of the total share capital of the company)	<b>Nil</b> <b>69222100</b> <b>100%</b> <b>52.15%</b>	Nil 69222100 100% 52.15%	Nil 69222100 100% 52.15%	Nil 69222100 100% 52.15%

	<b>Particulars</b>	<b>Quarter ended 30<sup>th</sup> June 2013</b>
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	11
	Disposed off during the quarter	11
	Remaining unresolved at the end of the quarter	Nil

**NOTES:**

1. The above results for the quarter ended 30<sup>th</sup> June 2013, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 3<sup>rd</sup> August, 2013 and were subjected to 'limited review' by the Auditors.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
3. As per Clause 41 of the listing agreement, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.

4. Details of forex gain/loss are given below:

	<b>Quarter ended 30.06.2013</b>	Quarter ended 31.03.2013	Quarter ended 30.06.2012	Year Ended 31.03.2013
	<b>Rs. Lakhs</b>	Rs. Lakhs	Rs. Lakhs	Rs. Lakhs
<b>Forex gain/(loss)</b>	<b>4253</b>	<b>(975)</b>	3005	1516

Forex gain has been included in Other Income and forex loss has been included in Other Expenses.

5. Figures for the previous year/period have been regrouped or recasted, wherever necessary.
6. Figures in respect of the results for preceding quarter ended 31<sup>st</sup> March, 2013 are the balancing figures between audited figures in respect of the financial year ended 31<sup>st</sup> March, 2013 and the published year-to-date figures upto the third quarter ended 31<sup>st</sup> December, 2012.

for Divi's Laboratories Limited

Place: Hyderabad  
Date: 3<sup>rd</sup> August, 2013

Dr. Murali K. Divi  
Chairman & Managing Director